Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design.
作者信息
Kim Chul, Giaccone Giuseppe
机构信息
Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA.
出版信息
Ann Transl Med. 2016 Dec;4(23):466. doi: 10.21037/atm.2016.11.48.
Abstract
摘要
相似文献
1
Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design.从癌症战争中的BATTLE-2中吸取的经验教训：贝叶斯方法在临床试验设计中的应用。
Ann Transl Med. 2016 Dec;4(23):466. doi: 10.21037/atm.2016.11.48.
2
An overview of the design and conduct of the BATTLE trials.BATTLE试验的设计与实施概述。
Chin Clin Oncol. 2015 Sep;4(3):33. doi: 10.3978/j.issn.2304-3865.2015.06.07.
3
Lessons learned and advice from Vietnam war nurses: a qualitative study.越南战争护士的经验教训与建议：一项定性研究。
J Adv Nurs. 2005 Mar;49(6):600-7. doi: 10.1111/j.1365-2648.2004.03335.x.
4
A new BATTLE in the evolving war on cancer.在不断演变的癌症战争中打响新战役。
Cancer Discov. 2011 Jun;1(1):14-6. doi: 10.1158/2159-8274.CD-11-0044. Epub 2011 Jun 1.
5
Changes in the care of the battle casualty: lessons learned from the Falklands campaign.战斗伤员护理的变革：从福克兰群岛战役中汲取的经验教训。
Mil Med. 1999 May;164(5):336-40.
6
Psychiatric battle casualties: an intra- and interwar comparison.精神病战斗伤员：两次世界大战期间及战后的比较。
Br J Psychiatry. 2001 Mar;178:242-7. doi: 10.1192/bjp.178.3.242.
7
The origins of casualty evacuation and echelons of care: lessons learned from the American Civil War.伤员后送与医疗救治层级的起源：从美国内战中汲取的教训
Int J Trauma Nurs. 1999 Jan-Mar;5(1):5-9. doi: 10.1016/s1075-4210(99)90076-7.
9
10
Military issues.军事问题。
Psychiatr Clin North Am. 2004 Sep;27(3):459-71. doi: 10.1016/j.psc.2004.03.005.
引用本文的文献
1
Precision Oncology-The Quest for Evidence.精准肿瘤学——对证据的探索
J Pers Med. 2019 Sep 5;9(3):43. doi: 10.3390/jpm9030043.
2
Tumor molecular profiling of NSCLC patients using next generation sequencing.非小细胞肺癌患者的肿瘤分子谱分析采用下一代测序技术。
Oncol Rep. 2017 Dec;38(6):3419-3429. doi: 10.3892/or.2017.6051. Epub 2017 Oct 23.
3
Ethical considerations of neuro-oncology trial design in the era of precision medicine.精准医学时代神经肿瘤学试验设计的伦理考量
J Neurooncol. 2017 Aug;134(1):1-7. doi: 10.1007/s11060-017-2502-0. Epub 2017 May 29.
本文引用的文献
1
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.BATTLE-2研究：一项针对既往接受过治疗的晚期非小细胞肺癌患者的生物标志物整合靶向治疗研究。
J Clin Oncol. 2016 Oct 20;34(30):3638-3647. doi: 10.1200/JCO.2015.66.0084.
2
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.维利帕尼-卡铂治疗乳腺癌的适应性随机分组
N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749.
3
Adaptive Randomization of Neratinib in Early Breast Cancer.来那替尼在早期乳腺癌中的适应性随机化
N Engl J Med. 2016 Jul 7;375(1):11-22. doi: 10.1056/NEJMoa1513750.
4
K-Ras protein as a drug target.K-Ras蛋白作为一种药物靶点。
J Mol Med (Berl). 2016 Mar;94(3):253-8. doi: 10.1007/s00109-016-1382-7. Epub 2016 Mar 9.
5
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.在KRAS突变型和KRAS野生型晚期非小细胞肺癌中使用和不使用厄洛替尼的司美替尼。
Ann Oncol. 2016 Apr;27(4):693-9. doi: 10.1093/annonc/mdw008. Epub 2016 Jan 22.
6
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.KRAS突变影响接受一线含铂化疗的非小细胞肺癌患者的预后。
Oncotarget. 2015 Oct 20;6(32):34014-22. doi: 10.18632/oncotarget.5607.
7
Refining the treatment of NSCLC according to histological and molecular subtypes.根据组织学和分子亚型细化 NSCLC 的治疗。
Nat Rev Clin Oncol. 2015 Sep;12(9):511-26. doi: 10.1038/nrclinonc.2015.90. Epub 2015 May 12.
8
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.一项将MEK1/MEK2抑制剂曲美替尼（GSK1120212）与多西他赛对比用于KRAS突变的晚期非小细胞肺癌（NSCLC）的随机II期研究†。
Ann Oncol. 2015 May;26(5):894-901. doi: 10.1093/annonc/mdv072. Epub 2015 Feb 26.
9
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.晚期胸部恶性肿瘤的分子特征分析与靶向治疗：一项基于生物标志物的多臂、多组织学类型的II期篮式试验。
J Clin Oncol. 2015 Mar 20;33(9):1000-7. doi: 10.1200/JCO.2014.58.2007. Epub 2015 Feb 9.
10
Crizotinib in ROS1-rearranged non-small-cell lung cancer.克唑替尼用于ROS1重排的非小细胞肺癌
N Engl J Med. 2014 Nov 20;371(21):1963-71. doi: 10.1056/NEJMoa1406766. Epub 2014 Sep 27.
Zotero 插件